Harnessing the power of synthetic lipids in drug delivery
Progress in synthetic lipid nanoparticle-based delivery systems has led to the development of robust drug delivery systems. As seen in the new mRNA-based Covid-19 vaccine delivery systems, the synthetic lipid nanoparticles are providing stability throughout the delivery process and helping generate a stronger immunogenic response.
Roche launches PHESGO in India
This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection, reducing chair time for patients by 90 percent.
RESURGENCE THE OMICRON WAY
Air pollution reduces 8 years of life expectancy in India
End inequalities to meet the target of ending AIDS
Tricuspid valve repair helps patients with ‘leaky heart valves’ to do better
The study also found that the patients who underwent tricuspid valve repair along with mitral valve surgery did not have their condition (tricuspid regurgitation) advancing to a severe stage
Six-month-old gets liver transplant in Kerala
The girl is also one of the youngest to undergo portal vein stenting Doctors from VPS Lakeshore Hospital, Kochi, have recently carried out a successful liver transplant surgery on a...
Galactosemic cataract
A 3-year-old male was brought to us by his parents with complaints of bilateral progressive lenticular opacity since early childhood. Elsewhere child was diagnosed to have a developmental cataract and...
Intuitive launches new App for surgeons using da Vinci surgical systems
The mobile app is also part of Intuitive’s digital and data support strategy as it serves as a digital portal to many parts of the Intuitive ecosystem — connecting its...
Hemex enhances Gazelle platform to test beta thalassemia
December 11, 2021
Philips launches new AI-enabled innovations in MR imaging
December 11, 2021
India approves selumetinib for neurofibro matosis type 1 children
D rugs Controller General of India (DCGI) has cleared Selumetinib 10 mg and 25mg capsules for the treatment of Pediatric patients above 3 years of age and older with neurofibromatosis...
